What is Propanc Bio's earnings per share (EPS)?

Propanc Bio (PPCB) reported diluted earnings per share of $-371.22 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Propanc Bio Financials

PPCB

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE June

This page shows Propanc Bio (PPCB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial health score pending refresh

We are recalculating Propanc Bio's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

Propanc Bio passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 3 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.01x

For every $1 of reported earnings, Propanc Bio generates $0.01 in operating cash flow (-$405K OCF vs -$58.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-101.6x

Propanc Bio earns $-101.6 in operating income for every $1 of interest expense (-$57.3M vs $564K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$58.9M

Propanc Bio reported -$58.9M in net income in fiscal year 2025.

EPS (Diluted)

$-371.22

Propanc Bio earned $-371.22 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$12K

YoY-42.7%

5Y CAGR-29.0%

10Y CAGR-19.6%

Propanc Bio held $12K in cash against $538K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

464,471

Propanc Bio had 464,471 shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-423.7%

Propanc Bio's ROE was -423.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$224K

YoY-9.8%

5Y CAGR+4.4%

10Y CAGR+5.2%

Propanc Bio invested $224K in research and development in fiscal year 2025. This represents a decrease of 9.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

PPCB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$224K-9.8%	$248K+0.1%	$248K-3.2%	$256K	N/A	$180K
SG&A Expenses	$57.0M	N/A	N/A	N/A	N/A	N/A
Operating Income	-$57.3M	N/A	N/A	N/A	N/A	N/A
Interest Expense	$564K	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	-$129K+0.5%	-$130K-136.2%	-$55K	N/A	-$135K
Net Income	-$58.9M	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$-371.22	$-35324.35	$-1.80	$-49.23	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$170K+750.0%	$20K-66.8%	$60K	N/A	$54K-0.5%	$54K-11.9%	$62K	N/A
SG&A Expenses	$6.2M+71.4%	$3.6M-21.1%	$4.6M	N/A	$53.1M+34451.1%	$154K-30.4%	$221K	N/A
Operating Income	-$6.4M-75.1%	-$3.7M+21.8%	-$4.7M	N/A	-$53.1M-24798.4%	-$213K+26.6%	-$291K	N/A
Interest Expense	$38K-35.1%	$59K-80.7%	$306K	N/A	$104K-12.5%	$119K+37.9%	$86K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$6.4M-105.7%	-$3.1M+36.1%	-$4.8M	N/A	-$54.1M	N/A	N/A	N/A
EPS (Diluted)	$-7.09-2263.3%	$-0.30+23.1%	$-0.39	N/A	$-312.46	$-32.23	$-35.97	N/A

PPCB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$19.6M+27028.9%	$72K+20.0%	$60K-26.1%	$82K+523.2%	$13K-86.7%	$99K
Current Assets	$8.4M+32732.1%	$25K+33.6%	$19K+26.7%	$15K+127.9%	$7K-90.4%	$69K
Cash & Equivalents	$12K-42.7%	$21K+109.9%	$10K+147.0%	$4K+80.4%	$2K-96.6%	$67K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.7M+48.7%	$3.9M+21.2%	$3.2M+2.3%	$3.1M+0.8%	$3.1M-17.6%	$3.7M
Current Liabilities	$5.6M+47.1%	$3.8M+20.1%	$3.2M+3.1%	$3.1M-0.6%	$3.1M-17.6%	$3.7M
Long-Term Debt	$538K+34.7%	$399K+2.2%	$391K-57.8%	$926K+48.3%	$625K-59.9%	$1.6M
Total Equity	$13.9M+468.0%	-$3.8M-21.2%	-$3.1M-3.1%	-$3.0M+1.4%	-$3.1M+15.8%	-$3.6M
Retained Earnings	-$125.6M-88.3%	-$66.7M-3.1%	-$64.7M-5.1%	-$61.6M-5.8%	-$58.2M-4.3%	-$55.8M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$14.3M-5.1%	$15.1M-15.9%	$18.0M-8.4%	$19.6M-12.9%	$22.5M+28585.2%	$79K+23.4%	$64K-12.1%	$72K
Current Assets	$8.2M+6.7%	$7.7M-12.1%	$8.8M+4.9%	$8.4M-14.2%	$9.7M+54037.3%	$18K-16.5%	$22K-15.4%	$25K
Cash & Equivalents	$444K-20.9%	$561K-6.9%	$603K+4886.2%	$12K-76.2%	$51K+246.9%	$15K+57.9%	$9K-56.0%	$21K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.5M-4.2%	$3.7M+1.2%	$3.6M-36.9%	$5.7M+29.1%	$4.4M+4.7%	$4.2M+1.6%	$4.2M+8.3%	$3.9M
Current Liabilities	$3.5M-4.1%	$3.6M+1.4%	$3.6M-36.0%	$5.6M+28.5%	$4.3M+4.5%	$4.2M+1.3%	$4.1M+8.1%	$3.8M
Long-Term Debt	$55K0.0%	$55K-48.6%	$107K-80.1%	$538K+22.7%	$439K+7.0%	$410K+7.3%	$382K-4.4%	$399K
Total Equity	$9.8M-6.0%	$10.5M-27.2%	$14.4M+3.3%	$13.9M-23.1%	$18.1M+535.0%	-$4.2M-1.2%	-$4.1M-8.7%	-$3.8M
Retained Earnings	-$140.8M-4.7%	-$134.5M-3.1%	-$130.5M-3.9%	-$125.6M-3.3%	-$121.6M-80.1%	-$67.5M-0.6%	-$67.1M-0.5%	-$66.7M

PPCB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$405K	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$491K	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$1.1M-14.3%	-$999K+48.5%	-$1.9M-2003.4%	-$92K+4.2%	-$96K-613.6%	$19K+108.0%	-$236K+9.4%	-$260K
Capital Expenditures	$154-93.2%	$2K-9.0%	$2K	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$1.1M-14.1%	-$1.0M+48.4%	-$1.9M	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$154+93.2%	-$2K+9.0%	-$2K	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$982K+1.7%	$965K-61.8%	$2.5M+3372.9%	$73K-50.7%	$147K+169.1%	$55K-74.6%	$216K-14.1%	$251K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PPCB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-423.7%	N/A	N/A	N/A	N/A	N/A
Return on Assets	-300.1%	N/A	N/A	N/A	N/A	N/A
Current Ratio	1.50+1.5	0.010.0	0.010.0	0.000.0	0.00-0.0	0.02
Debt-to-Equity	0.04	N/A	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-64.7%-35.1pp	-29.6%+4.1pp	-33.7%	N/A	-298.8%	N/A	N/A	N/A
Return on Assets	-44.4%-23.9pp	-20.5%+6.5pp	-26.9%	N/A	-240.0%	N/A	N/A	N/A
Current Ratio	2.37+0.2	2.13-0.3	2.45+1.0	1.50-0.7	2.24+2.2	0.000.0	0.010.0	0.01
Debt-to-Equity	0.010.0	0.010.0	0.01-0.0	0.04+0.0	0.02	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Akari Therapeutics Plc AKTX

$15.2M

Lixte Biotechnology Hldgs Inc LIXT

$125.4M

Allarity ALLR

$18.9M

BOUNDLESS BIO INC BOLD

$57.8M

Rein Therapeutics, Inc. RNTX

$67.7M

Frequently Asked Questions

Is Propanc Bio profitable?

No, Propanc Bio (PPCB) reported a net income of -$58.9M in fiscal year 2025.

How much debt does Propanc Bio have?

As of fiscal year 2025, Propanc Bio (PPCB) had $12K in cash and equivalents against $538K in long-term debt.

What is Propanc Bio's return on equity (ROE)?

Propanc Bio (PPCB) has a return on equity of -423.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Propanc Bio's operating cash flow?

Propanc Bio (PPCB) generated -$405K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Propanc Bio's total assets?

Propanc Bio (PPCB) had $19.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Propanc Bio spend on research and development?

Propanc Bio (PPCB) invested $224K in research and development during fiscal year 2025.

How many shares does Propanc Bio have outstanding?

Propanc Bio (PPCB) had 464,471 shares outstanding as of fiscal year 2025.

What is Propanc Bio's current ratio?

Propanc Bio (PPCB) had a current ratio of 1.50 as of fiscal year 2025, which is considered adequate.

What is Propanc Bio's debt-to-equity ratio?

Propanc Bio (PPCB) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Propanc Bio's return on assets (ROA)?

Propanc Bio (PPCB) had a return on assets of -300.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Propanc Bio's cash runway?

Based on fiscal year 2025 data, Propanc Bio (PPCB) had $12K in cash against an annual operating cash burn of $405K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Propanc Bio's Piotroski F-Score?

Propanc Bio (PPCB) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Propanc Bio's earnings high quality?

Propanc Bio (PPCB) has an earnings quality ratio of 0.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Propanc Bio cover its interest payments?

Propanc Bio (PPCB) has an interest coverage ratio of -101.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.